Trial · NCT00092547
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18 | qHPV Vaccine in Base Study | 6 | participants | ||
| Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18 | Placebo in Base Study | 0 | participants | ||
| Number of Participants Reporting SAEs From Month 18 Through Month 37 | qHPV Vaccine in Base Study | 0 | participants | ||
| Number of Participants Reporting SAEs From Month 18 Through Month 37 | qHPV Vaccine in Extension Study | 3 | participants | ||
| Number of Participants Reporting Other (Non-serious) AEs Through Month 18 | qHPV Vaccine in Base Study | 918 | participants | ||
| Number of Participants Reporting Other (Non-serious) AEs Through Month 18 | Placebo in Base Study | 340 | participants | ||
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 6: n=475, 151 | 93.3 | 95% Confidence Interval 90.6 to 95.3 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 6: n=475, 151 | 91.4 | 95% Confidence Interval 85.7 to 95.3 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 11: n=475, 151 | 96.0 | 95% Confidence Interval 93.8 to 97.6 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 11: n=475, 151 | 96.7 | 95% Confidence Interval 92.4 to 98.9 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 16: n=473, 154 | 97.9 | 95% Confidence Interval 96.1 to 99.0 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 16: n=473, 154 | 97.4 | 95% Confidence Interval 93.5 to 99.3 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 18: n=477, 160 | 74.4 | 95% Confidence Interval 70.3 to 78.3 | Percentage of participants |
| Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 18: n=477, 160 | 79.4 | 95% Confidence Interval 72.3 to 85.4 | Percentage of participants |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 6: n=475, 151 | 118.9 | 95% Confidence Interval 108.4 to 130.4 | milliMerck units/mL |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 6: n=475, 151 | 113.9 | 95% Confidence Interval 95.7 to 135.6 | milliMerck units/mL |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 11: n=475, 151 | 135.7 | 95% Confidence Interval 122.6 to 150.3 | milliMerck units/mL |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 11: n=475, 151 | 137.9 | 95% Confidence Interval 114.9 to 165.5 | milliMerck units/mL |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Base Study | Type 16: n=473, 154 | 521.2 | 95% Confidence Interval 466.2 to 582.6 | milliMerck units/mL |
| Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72 | qHPV Vaccine in Extension Study | Type 16: n=473, 154 | 485.8 | 95% Confidence Interval 396.4 to 595.3 | milliMerck units/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00092547/results